GENMAB Inactive Instrument
Genmab Share Price Nasdaq Copenhagen
Equities
DK0010272202
Biotechnology & Medical Research
| Sales 2024 * | 19.79B 2.85B 228B | Sales 2025 * | 23.61B 3.4B 272B | Capitalization | 129B 18.64B 1,492B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.67B 673M 53.86B | Net income 2025 * | 6.65B 959M 76.72B | EV / Sales 2024 * | 5.22 x |
| Net cash position 2024 * | 26.11B 3.76B 301B | Net cash position 2025 * | 33.02B 4.76B 381B | EV / Sales 2025 * | 4.08 x |
| P/E ratio 2024 * |
29.2
x | P/E ratio 2025 * |
21
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on Genmab
More recommendations
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 31/12/98 | |
Anthony Pagano
DFI | Director of Finance/CFO | 46 | 31/12/06 |
Anthony Mancini
COO | Chief Operating Officer | 53 | 22/03/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Deirdre Connelly
CHM | Chairman | 63 | 31/12/16 |
| Director/Board Member | 73 | 31/10/03 | |
Rolf K. Hoffmann
BRD | Director/Board Member | 64 | 31/12/15 |
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
01/08/2024
- Q2 2024 Earnings Release
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| +2.93% | 106B | |
| +7.02% | 23.47B | |
| -14.60% | 21.9B | |
| -38.55% | 17.85B | |
| -8.83% | 16.78B | |
| +5.51% | 14.41B | |
| +37.49% | 12.86B | |
| +329.39% | 8.78B | |
| -24.02% | 8.37B |
